The German biotech Evotec AG is to use its BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) model, an integrated fund and reward model, to form a new partnership withArix BioSciences PLC, LAB591. Together with the Fred Hutchinson Cancer Research Center, the three partners will jointly select promising research projects from the laboratories of the cancer research center, which is based in Seattle. The initial term of LAB591 is five years.
Once a research project has been chosen, Evotec will collaborate with Fred Hutchison on the research, seed-funded by Arix. Depending...






